1. Pneumatosis cystoides intestinalis after chemotherapy for hematological malignancies: report of 4 cases.

2. Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome.
   Chinushi M, Aizawa Y, Furushima H, Inuzuka H, Ojima K, Shibata A.

3. Preferential action of mexiletine on central common pathway of reentrant ventricular tachycardia.
   Aizawa Y, Abe A, Ohira K, Furushima H, Chinushi M, Fujita S.
   *J Am Coll Cardiol.* 1996 Dec;28(7):1759-64.

4. Coronary artery perforation with subepicardial hematoma.

5. Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans.

6. Repetitive ventricular responses induced by radiofrequency ablation for idiopathic ventricular tachycardia originating from the outflow tract of the right ventricle.
   Chinushi M, Aizawa Y, Ohhira K, Fujita S, Shiba M, Niwano S, Furushima H.

7. The usefulness of Holter monitoring in selecting pharmacologic therapy for patients with sustained monomorphic ventricular tachycardia: studies in patients in whom
no effective pharmacologic therapy could be determined by electrophysiologic study.

Niwano S, **Furushima H**, Taneda K, Abe A, Ohira K, Aizawa Y.  

8. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.

Naitoh N, **Furushima H**, Ohira K, Taneda K, Aizawa Y.  

9. Intracoronary acetylcholine-induced prolongation of monophasic action potential in long QT syndrome.  

10. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.

Naitoh N, Taneda K, Tagawa M, **Furushima H**, Yamaura M, Aizawa Y.  

11. The use of the block cycle length as a safe and efficient means of interrupting sustained ventricular tachycardia and its pharmacological modification.

Ohira K, Niwano S, **Furushima H**, Taneda K, Chinushi M, Aizawa Y.  

12. Comparison of arrhythmogenicity of atrial pacing at several right atrial pacing sites: evaluation of canine atrial electrograms during atrial pacing and arrhythmogenicity for atrial fibrillation.

Niwano S, Yamaura M, Washizuka T, Tanabe Y, **Furushima H**, Taneda K, Aizawa Y.  


Naitoh N, Tagawa M, Yamaura M, Taneda K, **Furushima H**, Aizawa Y.  
14. Effect of atropine on QT prolongation and torsade de pointes induced by intracoronary acetylcholine in the long QT syndrome.


15. Autonomic nerve activity and long QT interval syndrome: a role of acetylcholine and alpha-adrenoceptor.

Aizawa Y, **Furushima H**, Chinushi M, Washizuka T.


16. Both low and high energy cardioversion induced accelerated ventricular tachycardia in a patient treated with an implantable cardioverter defibrillator.

Washizuka T, Chinushi M, Hatada K, Kasai H, Ohhira K, **Furushima H**, Aizawa Y.


**Furushima H**, Chinushi M, Washizuka T, Aizawa Y.


18. Correlation between the effective refractory period and activation-recovery interval calculated from the intracardiac unipolar electrogram of humans with and without dl-sotalol treatment.

Chinushi M, Tagawa M, Kasai H, Washizuka T, Abe A, **Furushima H**, Aizawa Y.


19. Discrepancy between inducibility of ventricular tachycardia and activity of cardiac sarcoidosis. Requirement of defibrillator implantation for the inactive stage of cardiac sarcoidosis.

Mezaki T, Chinushi M, Washizuka T, **Furushima H**, Chinushi Y, Ebe K, Okumura H, Aizawa Y.


20. Inappropriate discharges by fourth generation implantable cardioverter defibrillators in patients with ventricular arrhythmias.


21. Arrhythmogenesis of T wave alternans associated with surface QRS complex alternans and the role of ventricular prematurity: observations from a canine model of LQT3 syndrome.
Chinushi M, Hosaka Y, Washizuka T, Furushima H, Aizawa Y.


22. Activation-recovery interval as a parameter to assess the intracardiac ventricular repolarization in patients with congenital long QT syndrome.
Chinushi M, Washizuka T, Hosaka Y, Furushima H, Tanabe Y, Chinushi Y, Aizawa Y.


23. Suppression of electrical storm by biventricular pacing in a patient with idiopathic dilated cardiomyopathy and ventricular tachycardia.


24. Microdislodgment of ventricular pacing lead undetectable during rapid pacing one year after implantation.
Chinushi Y, Chinushi M, Furushima H, Tanabe Y, Washizuka T, Aizawa Y.


25. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome.
Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y.


Furushima H, Chinushi M, Sugiura H, Aizawa Y.


28. Potential candidates for cardiac resynchronization therapy in Japanese patients with idiopathic dilated cardiomyopathy--a Niigata multicenter study of DCM--.

29. Unsuccessful internal defibrillation in Brugada syndrome: focus on refractoriness and ventricular fibrillation cycle length.

30. Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias.


32. Effects of intravenous magnesium in a prolonged QT interval model of polymorphic ventricular tachycardia focus on transmural ventricular repolarization.

33. Similarities between Brugada syndrome and ischemia-induced ST-segment elevation. Clinical correlation and synergy.
Chinushi M, Furushima H, Tanabe Y, Washizuka T, Aizawaz Y.
34. Inappropriate discharges of intravenous implantable cardioverter defibrillators owing to lead failure.

35. Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmias.

36. Elimination of late potentials by quinidine in a patient with Brugada syndrome.

37. Relationship between dominant prolongation of the filtered QRS duration in the right precordial leads and clinical characteristics in Brugada syndrome.


39. Ventricular tachycardia late after repair of congenital heart disease: efficacy of combination therapy with radiofrequency catheter ablation and class III antiarrhythmic agents and long-term outcome.


40. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.


41. Decrease in amplitude of intracardiac ventricular electrogram and inappropriate therapy in patients with an implantable cardioverter defibrillator.


42. Role of autonomic nervous activity in the antiarrhythmic effects of magnesium sulfate in a canine model of polymorphic ventricular tachyarrhythmia associated with prolonged QT interval.
Chinushi M, Izumi D, Komura S, Ahara S, Satoh A, **Furushima H**, Washizuka T, Aizawa Y.


43. Multiple premature beats triggered ventricular arrhythmias during pilsicainide infusion in a patient with inferior ST-segment elevation.
Chinushi M, Izumi D, **Furushima H**, Watanabe H, Aizawa Y.


44. Bepridil for drug-refractory ventricular tachyarrhythmias.
Izumi D, Chinushi M, **Furushima H**, Watanabe H, Washizuka T, Okamura K, Komura S, Tanabe Y, **Furushima H**, Aizawa Y.


45. Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome.
Chinushi M, Komura S, Izumi D, **Furushima H**, Tanabe Y, Washizuka T, Aizawa Y.

46. Comparison of conduction delay in the right ventricular outflow tract between Brugada syndrome and right ventricular cardiomyopathy: investigation of signal average ECG in the precordial leads.


47. Effect of dl-sotalol on mortality and recurrence of ventricular tachyarrhythmias: ischemic compared to nonischemic cardiomyopathy.


48. Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome.


49. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy.

Watanabe H, Okamura K, Chinushi M, **Furushima H**, Tanabe Y, Kodama M, Aizawa Y.


50. Automatic R-wave and impedance testing with the modern patient alert system to reduce inappropriate implantable cardioverter defibrillator shocks due to lead fracture.

Chinushi M, Hosaka Y, Ikarashi N, Iijima K, **Furushima H**, Aizawa Y.


51. A post-QRS potential in Brugada syndrome: its relation to electrocardiographic pattern and possible genesis.


52. The Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Events (J-TRACE): a nation-wide, prospective large cohort study; the study design.

53. Ventricular repolarization gradients in a patient with takotsubo cardiomyopathy.

**Furushima H**, Chinushi M, Sanada A, Aizawa Y.

*Europace.* 2008 Sep;10(9):1112-5.

54. Preservation of renal function in response to cardiac resynchronization therapy.


*Circ J.* 2008 Nov;72(11):1794-9

55. Focal atrial tachycardia refractory to radiofrequency catheter ablation originating from right atrial appendage.

**Furushima H**, Chinushi M, Hosaka Y, Aizawa Y.


56. Ventricular fibrillation triggered during and after radiofrequency energy delivery to the site of origin of idiopathic right ventricular outflow tract arrhythmia.

Iijima K, Chinushi M, **Furushima H**, Hosaka Y, Izumi D, Aizawa Y.


57. Effects of verapamil on anterior ST segment and ventricular fibrillation cycle length in patients with Brugada syndrome.

Chinushi M, Iijima K, Tagawa M, Komura S, **Furushima H**, Aizawa Y.


58. Segmental conduction block in a low-voltage area suppressed macro-reentrant ventricular tachycardia after surgical repair of tetralogy of Fallot.

Chinushi M, Komura S, **Furushima H**, Aizawa Y.


59. Significance of Early Onset and Progressive Increase of Activation Delay During Premature Stimulation in Brugada Syndrome.


*Circ J.* 2009 Jun 17.

60. Pilsicainide-induced ST segment elevation and ST segment depression in two patients with variant forms of Brugada-type electrocardiographic abnormalities.
61. Correlation between surface and intracardiac electrocardiogram in a patient with inappropriate defibrillation shocks due to hyperkalemia.

62. Delayed Pericardial Effusion Due to Perforation of the Right Ventricular Outflow Tract by an ICD Lead.


64. Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. Prevention of vagal nerve activation induced shortening of the atrial action potential duration.


66. Fetal atrioventricular block and postpartum augmentative QT prolongation in a patient with long QT syndrome with KCNQ1 mutation.

67. Ventricular Tachyarrhythmia Associated with Hypertrophic Cardiomyopathy: Incidence, Prognosis, and Relation to Type of Hypertrophy.
68. Ventricular Fibrillation and Ventricular Tachycardia Triggered by Late-Coupled Ventricular Extrasystoles in a Brugada Syndrome Patient.
Chinushi M, Furushima H, Hosaka Y, Izumi D, Aizawa Y

69. Effects of Bepridil versus E-4031 on Transmural Ventricular Repolarization and Inducibility of Ventricular Tachyarrhythmias in the Dog.

70. Catheter Ablation of Ventricular Tachycardias Due to Forward and Reverse Propagation Across a Reentrant Circuit Inside a Nonischemic Biventricular Aneurysm.
Chinushi M, Izumi D, Furushima H, Aizawa Y.

71. Ischemia-induced prominent J waves in a patient with Brugada syndrome
Yagihara N, Sato A, Furushima H, Chinushi M, Hirono T, Aizawa Y.

72. Preexcitation unmasks J waves: 2 cases.

73. Randomized trial of angiotensin II-receptor blocker vs. Dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study).

74. Suppression of storms of ventricular tachycardia by epicardial ablation of isolated delayed potential in noncompaction cardiomyopathy.

75. Characteristics of J wave-associated ideopathic ventricular fibrillation: role of drugs.
Pacing Clin Electrophysiol 2011
77. Inappropriate pacing inhibition triggered by QT prolongation due to T wave oversensing in an ICD recipient presenting with long QT syndrome.
78. Epicardial Scar in a Patient with no Apparent Heart Disease.
79. The prevalence of early repolarization in Wolff-Parkinson-White syndrome with a special reference to J waves and the effects of catheter ablation.
81. Endocardial Arrhythmogenic Mechanisms of Torsades de Pointes in Patients with the Congenital Long QT Syndrome.
82. Intramural inflammation as a cause of transient ST-segment elevation in a patient of cardiac sarcoidosis.
84. Analysis of J waves during myocardial ischaemia.

*Europace* 2012; 14: 715-723.

85. Is coexistence of sustained ST-segment elevation and abnormal Q waves a risk factor for electrical storm in ICD patients with structural heart diseases?


*Europace* 2012; 14: 675-681.

86. An appropriate defibrillation threshold obtained by the combined connection between two shock leads and ICD generator


87. Significance and usefulness of heart rate variability in patients with multiple system atrophy

Furushima H, Shimohata T, Nakayama H, Ozawa T, Chinushi M, Aizawa Y, Nishizawa M.

*Movement Disorders* 2012; 27: 570-574.

88. The peak-to-end of the T wave in the limb ECG leads reflects total spatial rather than transmural dispersion of ventricular repolarization in an anthopleurin-A model of prolonged QT interval.


*Heart Rhythm* 2012; 9: 796-803.

89. Epicardial and endocardial mapping determine most successful site of ablation for ventricular tachyarrhythmias originating from left ventricular summit.

Iijima K, Chinushi M, Furushima H, Aizawa Y.

*Europace* 2012; 14: 911-912.

90. Efficacy and safety of celevarone with amiodarone as calibrator in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death the ALPHEE study

ALPHEE Study Investigators (Furushima H)

*Circulation* 20111 124: 2649-2660.

91. Early repolarization and its modification by preexcitation in two patients with intermittent Wolff-Parkinson-White syndrome.

Hasegawa K, Sato A, Watanabe H, Furushima H, Chinushi M, Aizawa Y.

*Pacing Clin Electrophysiol* 2012; 20
92. Nifekalant enlarged the transmural activation-recovery interval difference as well as the peak-to-end interval on surface ECG in a patient with short QT syndrome. Chinushi M, Sato A, Izumi D, Furushima H. J Cardiovascular Electrophysiol 2012; 11


Okamura T, Hori M; J-Land Investigators (Furushima H). 

100. Malfunction of cardiac resynchronization therapy due to subsequent fracture of the ring and tip conductors of a co-radial left ventricular bipolar lead. 
Sato A, Chinushi M, Izumi D, Furushima H, Minamino T. 

101. Augmentation of the J wave by rapid pacing in a patient with vasospastic angina. 
Sato A, Watanabe H, Sonoda K, Chinushi M, Tsuda T, Izumi D, Furushima H, Minamino T. 

102. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land Study. 

103. Appropriate duration of driving restrictions after inappropriate therapy from implantable cardiac shock devices-interim analysis of the Nippon Storm Study. 

104. Frequency characteristics and associations with the defibrillation threshold of ventricular fibrillation in patients with implantable cardioverter defibrillators. 

105. Electrical stimulation based evaluation for functional modification of renal autonomic nerve activities induced by catheter ablation. 
Heart Rhythm 2016; 16: 30262-4

106. Sustained ventricular tachycardia developed following successful ablation of target idiopathic left ventricular premature complexes. 
Tagawa M, Ochiai Y, Nakamura Y, Furushima H, Chinushi M 
Int J Cardiol 2016; 1:222: 686-8

107. Trends and determinant factors in the use of cardiac resynchronization therapy


Chinushi M, Saitoh O, Watanabe J, Sugai A, Suzuki K, Hosaka Y, Furushima H

*Pacing Clin Electrophysiol* 2017; 40 :223-231

109. The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias.

*J Electrocardiol* 2017; 50 :277-281